Side effects of cancer treatment with recombinant human tumour necrosis factor alpha: A new challenge for the intensive care unit

Clinical Intensive Care

Volumn 8, Issue 3, 1997, Pages 142-150

  Zwaveling, J H ^a   Maring, J K ^a   Girbes, A R J ^a   Schraffordt Koops, H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Isolated limb perfusion; Toxicity; Tumour necrosis factor alpha (TNF )

Indexed keywords

RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

BLOOD TOXICITY; CANCER; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTENSION; INTENSIVE CARE; LIMB PERFUSION; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; RESPIRATORY FAILURE; REVIEW;

EID: 0030759213     PISSN: 09563075     EISSN: None     Source Type: Journal    
DOI: 10.3109/tcic.8.3.142.150     Document Type: Review

References (81)